



TISSUE THERAPIES

ASX ANNOUNCEMENT

12 October 2004

Tissue Therapies Strengthens Financial Resources

Biomedical company, **Tissue Therapies Limited (ASX: TIS)** today announced that it has strengthened its financial resources and share register with the completion of a placement to institutional investors and sophisticated investors.

The Company has placed 2,000,000 new ordinary shares with institutional and sophisticated investors at \$0.73 per share to raise \$1.46 million before costs associated with the issue.

The placement of new shares has been conducted in accordance with ASX Listing Rule 7.1 and represents an additional 14.86 % of the Company's existing issued capital.

The net proceeds of the issue provides further working capital to assist with acceleration of emerging commercial opportunities in cell culture and wound healing, and also adds strength to the Company's balance sheet to assist with future commercial negotiations.

The placement was coordinated by ABN AMRO Morgans, the underwriter of the Company's successful initial public offer. Settlement is scheduled for Friday, 15 October.

ENDS

Further information or for an interview:

Greg Baynton
Executive Director, Tissue Therapies Limited
Telephone: 0414 970 566

About Tissue Therapies Limited

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue and various cell culture applications.

The Company has worldwide exclusive rights to commercialise VitroGro®, a platform technology developed by tissue engineering experts within QUT's Institute of Health and Biomedical Innovation (IHBI) for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration and cell culture.

Based on its VitroGro® platform technology, Tissue Therapies is developing more effective medical treatments for wounds and burns, integration of orthopaedic and medical implants, and other applications such as cosmeceuticals.

Tissue Therapies also provides cell culture reagents to enhance the growth of mammalian cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.

More information: www.tissuetherapies.com